Q1 EPS Forecast for Esperion Therapeutics Lifted by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Zacks Research upped their Q1 2026 earnings estimates for Esperion Therapeutics in a report issued on Monday, July 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of ($0.15) for the quarter, up from their prior forecast of ($0.16). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ FY2026 earnings at ($0.22) EPS and Q1 2027 earnings at ($0.17) EPS.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Esperion Therapeutics had a negative net margin of 59.03% and a negative return on equity of 0.91%. The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $54.97 million.

A number of other research analysts have also commented on the stock. The Goldman Sachs Group lowered their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a research note on Thursday, April 17th. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, June 17th. Finally, Needham & Company LLC reduced their target price on shares of Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $7.00.

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $1.41 on Wednesday. Esperion Therapeutics has a 12 month low of $0.69 and a 12 month high of $3.94. The firm has a market capitalization of $279.46 million, a PE ratio of -1.76 and a beta of 0.70. The company’s 50 day simple moving average is $1.13 and its 200 day simple moving average is $1.35.

Institutional Trading of Esperion Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Boomfish Wealth Group LLC boosted its holdings in Esperion Therapeutics by 29.5% during the second quarter. Boomfish Wealth Group LLC now owns 45,306 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 10,309 shares in the last quarter. North Star Investment Management Corp. bought a new stake in Esperion Therapeutics during the second quarter worth approximately $25,000. UMB Bank n.a. bought a new stake in Esperion Therapeutics during the second quarter worth approximately $167,000. Sivia Capital Partners LLC acquired a new position in Esperion Therapeutics in the 2nd quarter worth approximately $25,000. Finally, Parallel Advisors LLC boosted its stake in Esperion Therapeutics by 1,174.2% in the 2nd quarter. Parallel Advisors LLC now owns 127,424 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 117,424 shares during the period. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.